Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $43.1 million.

  • Rocket Pharmaceuticals' Net Cash Flow rose 5978.44% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 10646.73%. This contributed to the annual value of $107.7 million for FY2024, which is 22735.84% up from last year.
  • Rocket Pharmaceuticals' Net Cash Flow amounted to $43.1 million in Q3 2025, which was up 5978.44% from -$17.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Net Cash Flow's 5-year high stood at $180.6 million during Q3 2023, with a 5-year trough of -$169.8 million in Q4 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' median Net Cash Flow value was -$17.0 million (recorded in 2025), while the average stood at -$11.7 million.
  • In the last 5 years, Rocket Pharmaceuticals' Net Cash Flow tumbled by 96947.63% in 2021 and then surged by 187756.24% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Cash Flow (Quarter) stood at -$12.9 million in 2021, then plummeted by 334.02% to -$56.2 million in 2022, then plummeted by 202.23% to -$169.8 million in 2023, then surged by 157.75% to $98.0 million in 2024, then tumbled by 56.01% to $43.1 million in 2025.
  • Its Net Cash Flow was $43.1 million in Q3 2025, compared to -$17.0 million in Q2 2025 and -$113.8 million in Q1 2025.